Prenatal omega-3 LCPUFA and symptoms of allergic disease and sensitization throughout early childhood – a longitudinal analysis of long-term follow-up of a randomized controlled trial

ConclusionMaternal supplementation with 900  mg of ω-3 LCPUFA did not change the progression of IgE-mediated allergic disease symptoms or sensitization throughout childhood from 1 to 6 years.Trial registrationAustralian New Zealand Clinical Trials Registry (ACTRN); DOMInO trialACTRN12605000569606, early childhood allergy follow upACTRN12610000735055 and 6-year allergy follow upACTRN12615000498594.
Source: World Allergy Organization Journal - Category: Allergy & Immunology Source Type: research